Published in the KeAi journal Dental Research , a new study elucidates the molecular mechanisms preventing the resolution of diabetic periodontitis, a notoriously refractory complication of diabetes. The research team from Chongqing Medical University identified excessive fibrin deposition as the primary pathological scaffold driving chronic inflammation, and demonstrated that a targeted peptide can effectively resolve the disease.
"Patients with diabetes often exhibit a hypofibrinolytic state, leading to impaired tissue healing," explains senior author Jinlin Song, Dean and Professor of College of Stomatology at the university "The periodontal cavity, this translates to severe alveolar bone loss and persistent mucosal damage. Previously, the exact mechanism sustaining this localized inflammation was not fully understood."
The researchers discovered that uncleared fibrin continuously activates macrophages via the Mac-1 receptor, locking them in a pro-inflammatory (M1) state. "This triggers a downstream cascade where γδ T cells produce excessive IL-17A, ultimately destroying the protective claudin-1-dependent epithelial barrier of the gums," says Song.
To counteract this, the team then utilized an engineered fibrin-blocking peptide, 377P. In diabetic mouse models, locally administering 377P competitively inhibited the fibrin-Mac-1 interaction. This intervention successfully suppressed the inflammatory signaling, restored tight junctions in the gum tissue, and significantly promoted periodontal bone regeneration.
"While hyperglycemia acts as the initial trigger, our data suggest that uncleared fibrin serves as a persistence signal that prevents the inflammatory response from resolving," notes Song. "By specifically inhibiting the fibrin-Mac-1 axis with the 377P peptide, we can break this feed-forward loop and restore immune homeostasis without compromising basal host defense."
Notably, the researchers observed similar fibrin-macrophage co-localization in other organs, such as adipose tissue under diabetic conditions. "This suggests that targeting fibrin-mediated immunopathology could represent a universal therapeutic strategy for various immune-mediated diabetic comorbidities beyond oral health," adds Song.
###
Contact the author: Jinlin Song, College of Stomatology, Chongqing Medical University, songjinlin@hospital.cqmu.edu.cn
The publisher KeAi was established by Elsevier and China Science Publishing & Media Ltd to unfold quality research globally. In 2013, our focus shifted to open access publishing. We now proudly publish more than 200 world-class, open access, English language journals, spanning all scientific disciplines. Many of these are titles we publish in partnership with prestigious societies and academic institutions, such as the National Natural Science Foundation of China (NSFC).
Experimental study
Lab-produced tissue samples
Excessive fibrin deposition disrupts immune-epithelial crosstalk and impairs resolution of diabetes-associated periodontitis
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.